Salmeterol xinafoate
A long-acting beta2-adrenergic receptor agonist (Ki=1.5 nM) used clinically to treat asthma and maintenance of COPD. Asthma Approved (In Vitro) :Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation. (In Vivo) :Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD) .
Product Specifications
CAS Number
94749-08-3
Product Name Alternative
GR-33343X xinafoate
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 50 mg/mL
Smiles
C1=CC=C (C=C1) CCCCOCCCCCCNCC (C2=CC (=C (C=C2) O) CO) O.C1=CC=C2C (=C1) C=CC (=C2O) C (=O) O
Molecular Formula
C36H45NO7
Molecular Weight
603.745
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with 4-hydroxy-α1-[[[6- (4-phenylbutoxy) hexyl]amino]methyl]-1,3-benzenedimethanol (1:1)
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
High Sensitive Northern Blot Probes : miR-183-5p (HS)
SH3BGRL2 CRISPRa sgRNA lentivector (set of three targets)(Human)
Rabbit Polyclonal Seasonal H1N1 Hemagglutinin Antibody [CoraFluor 1]